On December 5, 2023, AbbVie Inc. and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat will utilize its Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple therapeutic targets. Wilson Sonsini Goodrich & Rosati advised BigHat on the transaction.

Under the terms of the agreement, BigHat will receive an upfront payment of $30 million and may be eligible to receive up to approximately $325 million in aggregate research and development milestones, with the potential for further commercial milestones, as well as tiered royalties on net sales.

The Wilson Sonsini team that advised BigHat on the transaction included:

Technology Transactions
Seth Flaum
Sarah Walker

Patents and Innovations
Julia Minitti
Derrick Rowe

For more information, please see the companies’ news release.